PA
MDXG icon

PharVision Advisers’s MiMedx Group MDXG Stock Holding History

PharVision Advisers’s Portfolio MDXG Stock Details MDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.1K Sell
13,955
-30,303
-68% -$153K 0.56% 83
2025
Q4 		$300K Buy
44,258
+26,986
+156% +$189K 0.15% 272
2025
Q3 		$121K Buy
+17,272
New +$120K 0.07% 602

Other funds holding MDXG

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

PharVision Advisers's MDXG Position: Q1 2026 in Review

PharVision Advisers reduced its MiMedx Group (MDXG) stake by 68% in Q1 2026, selling an estimated $153K and leaving 13,955 shares worth $55.1K. The position accounts for 0.56% of the portfolio, ranked #83.

PharVision Advisers first reported a position in MDXG in Q3 2025 and has held it in 3 quarters since. The position peaked at $300K in Q4 2025. 237 funds tracked by Wall St. Rank hold MDXG as of Q1 2026.

  • PharVision Advisers held 13,955 shares of MiMedx Group worth $55.1K as of Q1 2026.
  • PharVision Advisers sold 30,303 MiMedx Group shares in Q1 2026, an estimated $153K.
  • MiMedx Group made up 0.56% of PharVision Advisers's portfolio in Q1 2026, its #83 holding.
  • PharVision Advisers first reported a position in MiMedx Group in Q3 2025 and has held it in 3 quarters since.
  • PharVision Advisers's MiMedx Group position peaked at $300K in Q4 2025.
  • 237 funds tracked by Wall St. Rank held MiMedx Group as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.